PHE Stock Overview
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Cipher Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$6.00 |
52 Week High | CA$6.65 |
52 Week Low | CA$2.16 |
Beta | 1.04 |
1 Month Change | -3.23% |
3 Month Change | 54.64% |
1 Year Change | 170.27% |
3 Year Change | 633.50% |
5 Year Change | 568.90% |
Change since IPO | 127.27% |
Recent News & Updates
Recent updates
Shareholder Returns
PHE | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | 2.5% | 1.8% |
1Y | 170.3% | -27.7% | 2.2% |
Return vs Industry: PHE exceeded the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: PHE exceeded the German Market which returned 2.2% over the past year.
Price Volatility
PHE volatility | |
---|---|
PHE Average Weekly Movement | 8.3% |
Pharmaceuticals Industry Average Movement | 6.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PHE's share price has been volatile over the past 3 months.
Volatility Over Time: PHE's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | n/a | Craig Mull | www.cipherpharma.com |
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company’s licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults.
Cipher Pharmaceuticals Inc. Fundamentals Summary
PHE fundamental statistics | |
---|---|
Market cap | €145.24m |
Earnings (TTM) | €19.04m |
Revenue (TTM) | €19.77m |
7.6x
P/E Ratio7.3x
P/S RatioIs PHE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PHE income statement (TTM) | |
---|---|
Revenue | US$21.16m |
Cost of Revenue | US$4.07m |
Gross Profit | US$17.09m |
Other Expenses | -US$3.29m |
Earnings | US$20.38m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.85 |
Gross Margin | 80.77% |
Net Profit Margin | 96.32% |
Debt/Equity Ratio | 0% |
How did PHE perform over the long term?
See historical performance and comparison